Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells

New England Journal of Medicine

Volumn 362, Issue 11, 2010, Pages 1005-1013

  Greenberger, Shoshana ^a   Boscolo, Elisa ^a   Adini, Irit ^a   Mulliken, John B ^a   Bischoff, Joyce ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; DEXAMETHASONE; HYDROCORTISONE; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; PREDNISONE; SHORT HAIRPIN RNA; UROKINASE RECEPTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSPLANTATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; GENE SILENCING; HEMANGIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFANTILE HEMANGIOMA; INVOLUTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; UMBILICAL VEIN;

EID: 77949645298     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0903036     Document Type: Article

References (34)

1. Mulliken JB. Cutaneous vascular anomalies. Semin Vasc Surg 1993;6:204-18.
2. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg 2000; 37:517-84.
3. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341:173-81.
4. Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008; 153:712-5.
5. Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008;118:2592-9.
6. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001;107:745-52.
7. Khan ZA, Melero-Martin JM, Wu X, et al. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 2006;108:915-21.
8. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood 2007; 109:4761-8.
9. Zins K, Abraham D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007; 67:1038-45.
10. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 2005;168: 643-53. [Erratum, J Cell Biol 2005;169:541.]
11. Gaillard RC, Poffet D, Riondel AM, Saurat JH. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 1985;61:1009-11.
12. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93: 2357-64.
13. Chang J, Most D, Bresnick S, et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 1999;103:1-9.
14. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007;27: 2664-70.
15. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001;159:2271-80.
16. Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M. Insulinlike growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 2002; 99:7455-60.
17. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982;69:412-22.
18. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997;13:375-423.
19. Smoller BR, Apfelberg DB. Infantile (juvenile) capillary hemangioma: a tumor of heterogeneous cellular elements. J Cutan Pathol 1993;20:330-6.
20. Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J. Endothelial progenitor cells in infantile hemangioma. Blood 2004;103: 1373-5.
21. Edgerton MT. The treatment of hemangiomas: with special reference to the role of steroid therapy. Ann Surg 1976; 183:517-32.
22. Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14:1236-46.
23. Claesson-Welsh L. Healing hemangiomas. Nat Med 2008;14:1147-8.
24. Zhang L, Lin X, Wang W, et al. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg 2005;116:200-4.
25. Wu WS, Wang FS, Yang KD, Huang CC, Kuo YR. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol 2006;126:1264-71.
26. Wilson C, Scullin P, Worthington J, et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer 2008;99:2054-64.
27. Hata Y, Sassa Y, Kita T, et al. Vascular endothelial growth factor expression by hyalocytes and its regulation by glucocorticoid. Br J Ophthalmol 2008;92:1540-4.
28. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-15.
29. Cifone MG, Migliorati G, Parroni R, et al. Dexamethasone-induced thymocyte apoptosis: apoptotic signal involves the sequential activation of phosphoinositidespecific phospholipase C, acidic sphingomyelinase, and caspases. Blood 1999;93: 2282-96.
30. Zacharchuk CM, Mer?ep M, Chakraborti PK, Simons SS Jr, Ashwell JD. Programmed T lymphocyte death: cell activation-and steroid-induced pathways are mutually antagonistic. J Immunol 1990; 145:4037-45.
31. Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T, Komatsu Y. Inhibition by dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: a possible association with Bcl-xL induction. Hepatology 1998;27:959-66.
32. Oh HY, Namkoong S, Lee SJ, et al. Dexamethasone protects primary cultured hepatocytes from death receptor-mediated apoptosis by upregulation of cFLIP. Cell Death Differ 2006;13:512-23.
33. Isik FF, Rand RP, Gruss JS, Benjamin D, Alpers CE. Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 1996;61:71-6.
34. Hasan Q, Tan ST, Xu B, Davis PF. Effects of five commonly used glucocorticoids on haemangioma in vitro. Clin Exp Pharmacol Physiol 2003;30:140-4.